	US 11,766,490 B2
	Synthetic DNA vectors and methods of use
Bruce C. Schnepp, Havertown, PA (US); and Philip R. Johnson, Bryn Mawr, PA (US)
Assigned to Intergalactic Therapeutics, Inc., Cambridge, MA (US)
Filed by Intergalactic Therapeutics, Inc., Brighton, MA (US)
Filed on Jul. 1, 2021, as Appl. No. 17/365,846.
Application 17/365,846 is a continuation of application No. PCT/US2020/051507, filed on Sep. 18, 2020.
Claims priority of provisional application 62/902,084, filed on Sep. 18, 2019.
Prior Publication US 2021/0322579 A1, Oct. 21, 2021
Int. Cl. A61K 48/00 (2006.01); C12N 15/64 (2006.01); C12N 15/86 (2006.01)

CPC A61K 48/0066 (2013.01) [A61K 48/0058 (2013.01); C12N 15/64 (2013.01); C12N 15/86 (2013.01); C12N 2320/32 (2013.01); C12N 2750/14143 (2013.01); C12N 2830/50 (2013.01)]

28 Claims

1. A method of treating a cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a synthetic circular DNA vector comprising two or more genes encoding two or more therapeutic polypeptides, wherein the synthetic circular DNA vector lacks an origin of replication, a drug resistance gene, and a site-specific recombination recognition site, thereby treating the cancer, wherein the two or more genes are together greater than 10 Kb in size.